tiprankstipranks
Advertisement
Advertisement

KYKOF Stock Latest News

Kyowa Kirin downgraded to Sell from Buy at Citi
The FlyKyowa Kirin downgraded to Sell from Buy at Citi
2M ago
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Kyowa Kirin downgraded to Underweight from Equal Weight at Morgan Stanley
2M ago
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
PremiumThe Fly
Kyowa Kirin downgraded to Neutral from Outperform at SMBC Nikko
2M ago
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
PremiumThe Fly
Kyowa Kirin downgraded to Underweight from Neutral at JPMorgan
2M ago
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
PremiumThe Fly
Kyowa Kirin announces discontinuation of rocatinlimab clinical trials
2M ago
AMGN
KYKOF Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsKYKOF Upcoming Earnings Report: What to Expect?
3M ago
Kyowa Kirin to regain control of rocatinlimab development, commercialization
Premium
The Fly
Kyowa Kirin to regain control of rocatinlimab development, commercialization
3M ago
AMGN
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
Premium
The Fly
Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
4M ago
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
PremiumCompany Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
6M ago
KYKOF
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
PremiumCompany Announcements
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
6M ago
KYKOF
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
6M ago
KYKOF
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
PremiumCompany Announcements
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
6M ago
KYKOF
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
PremiumCompany AnnouncementsKyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
6M ago
KYKOF
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
Premium
Company Announcements
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
6M ago
KYKOF
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
Premium
Company Announcements
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
6M ago
KYKOF
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
6M ago
KYKOF
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
6M ago
KYKOF
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
6M ago
KYKOF
Kura Oncology receives $30M development milestone payment for ziftomenib
PremiumThe Fly
Kura Oncology receives $30M development milestone payment for ziftomenib
6M ago
KURA
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
PremiumThe FlyKura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
7M ago
KURA
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
Premium
Company Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
8M ago
KYKOF
Kyowa Kirin Earnings Call: Mixed Sentiment Amid Growth and Challenges
Premium
Company Announcements
Kyowa Kirin Earnings Call: Mixed Sentiment Amid Growth and Challenges
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >